Menu

Koala Immune Response to Genome-Inserting Retroviruses Identified

Small RNAs called piRNAs provide a first line of defense against the viruses.

Oct 11, 2019
Emily Makowski
ABOVE: © ISTOCK.COM, CRAIGRJD

Koalas are susceptible to cancers such as lymphoma and leukemia along with chlamydia infections due to koala retrovirus, a pathogen that began inserting itself into the koala genome about 40,000 years ago and is continuing to do so. A paper published in Cell yesterday (October 10) identifies an innate immune response in koalas infected with KoRV.

Viral DNA makes up about 8 percent of the human genome—but these insertions happened in our primate ancestors millions of years ago, so far back in evolutionary history that scientists haven’t been able to watch the process unfold in an animal before, reports STAT

“What [koalas] are going through is the process of what’s driven the evolution of every animal on the planet,” William Theurkauf, a geneticist at the University of Massachusetts Medical School and lead author of the study, tells The New York Times. For example, he says, a gene necessary for the placenta originally came from a virus millions of years ago. 

Theurkauf’s team studied small RNAs called piRNAs from tissue samples of koala testes, livers, and brains. They found that piRNAs provide a first-line defense against viruses by targeting foreign DNA that is moving around the genome. But the defenses don’t always hold up, allowing a virus to insert itself into the genome and get passed on to future generations. In addition to KoRV, four other viruses are also moving between koala genes. “It’s evolution in real time,” Theurkauf says to the Times. Through this research, scientists may begin to better understand how our own genome acquired viral DNA so long ago.

See “Koala Time Machine

Emily Makowski is an intern at The Scientist. Email her at emakowski@the-scientist.com.

November 2019

Oceanic Connections

Biologists consider the movements of marine animals

Marketplace

Sponsored Product Updates

Diagenode to Offer Single-Cell ATAC-Seq Services Featuring Bio-Rad’s Droplet Digital PCR Technology
Diagenode to Offer Single-Cell ATAC-Seq Services Featuring Bio-Rad’s Droplet Digital PCR Technology
Diagenode, Inc., a leading global provider of solutions for epigenetics research and sample preparation, and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced a partnership in which Diagenode will offer Single-Cell ATAC-Seq (scATAC-Seq) Services, featuring Bio-Rad’s Droplet Digital PCR technology, to help advance epigenomics research.
Bio-Rad Introduces EveryBlot Blocking Buffer that Offers 5-Minute Blocking Time and Greater Sensitivity for Western Blots
Bio-Rad Introduces EveryBlot Blocking Buffer that Offers 5-Minute Blocking Time and Greater Sensitivity for Western Blots
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of EveryBlot Blocking Buffer, a western blot blocking reagent that offers 5-minute blocking time and produces higher signal and lower background levels resulting in greater sensitivity for western blots compared to other available blocking buffers.
TTP plc Desktop Biology enables development and manufacture of DnaNudge technology
TTP plc Desktop Biology enables development and manufacture of DnaNudge technology
·        Novel multiplex technology developed to help consumers make healthier choices based on their genetic profile·        TTP involved with all aspects of product development, from initial concept to prototype testing and manufacture·        Culmination of technology and product development partnership spanning just over 3 years
Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services
Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services
Targos Molecular Pathology GmbH, a market leader in clinical biomarker services announced today a technology partnership with Ultivue, the innovation leader in multiplex tissue biomarker assays, to offer the biopharmaceutical industry new capabilities to improve the characterization of cancer patients’ samples selected for clinical research programs.